Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity

Matthew Anson; Sizheng Steven Zhao; Hani Essa; Philip Austin; Gema Hernández; Professor Gregory Lip; Uazman Alam

doi:10.1016/j.clinthera.2023.07.026

Related publications

Article2025

Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study

William Yang Wang, Pamela B. Davis, Xin Qi, Mark E. Gurney, George Perry, Nora D. Volkow, David C. Kaelber, Rong Xu

Article2006

Ethnicity, Obesity, and Risk of Type 2 Diabetes in Women

Iris Shai, Rui Jiang, JoAnn E. Manson, Meir J. Stampfer, Walter C. Willett, Graham A. Colditz, Frank B Hu

Article2012

Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis

Davide Soranna, Lorenza Scotti, Antonella Zambon, Cristina Bosetti, Guıdo Grassı, Alberico L. Catapano, Carlo La Vecchia, Giuseppe Mancia, Giovanni Corrao

Article2023

Dementia risk in patients with type 2 diabetes: Comparing metformin with no pharmacological treatment

Bang Zheng, Bowen Su, Sara Ahmadi‐Abhari, Dimitrios Kapogiannis, Ioanna Tzoulaki, Elio Riboli, Lefkos Middleton

Article2015

Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study

Ann‐Lii Cheng, Yoon‐Koo Kang, Aiwu Ruth He, Ho Yeong Lim, Baek‐Yeol Ryoo, Chao‐Hung Hung, I‐Shyan Sheen, Namiki Izumi, TaShara Austin, Qiang Wang, Jonathan Greenberg, Shinichi Shiratori, Robert A. Beckman, Masatoshi Kudo